Search...
Rallybio posts Q3 net income of $16 million
I'm PortAI, I can summarize articles.
Rallybio Corporation reported a Q3 net income of $16 million, or $0.36 per share, a turnaround from a net loss of $11.5 million in Q3 2024. As of September 30, 2025, the company had $59.3 million in cash and marketable securities. Rallybio generated $20 million from selling its interest in REV102 to Recursion Pharmaceuticals and advanced its lead program, RLYB116, completing dosing in Cohort 1 of its Phase 1 study, with data from Cohort 2 expected in Q4 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments